From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Insider dealing at e-Therapeutics – let’s see if AIM Regulation and the FCA are awake today

By Ben Turney | Thursday 26 February 2015


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


e-Therapeutics (ETX) has just issued this statement about the >35% jump in its share price in the last few days. In short, its board has admitted that it thinks price sensitive information has leaked from the company. “Big deal”, I hear our regular readers cry, “this is what we expect on AIM”. Sadly I have to agree with this sentiment, but this instance of seemingly clear-cut insider dealing has caught my eye. This is because, on this occasion, the London Stock Exchange’s AIM Regulation team and Financial Conduct Authority should have an easy time of catching the culprit or culprits. That is, if they are awake. It is, after all, Thursday afternoon.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 14:45:56